Dycem Contamination Control

Effective, Efficient & Sustainable Contamination Control Mats.

Contamination: The Risk to Pharmaceutical & Biotechnology Companies

A strong contamination control strategy ensures top-quality products, compliance with FDA and other regulations, and safeguards the health and safety of users.

Manufacturing introduces contamination risks from personnel, raw materials, equipment, and processes, leading to threats like compromised safety, quarantines, recalls, and shutdowns. For companies, these risks are too significant to overlook.

Effective floor-level contamination control is crucial for GMP-compliant facilities. Dycem mats, integrated into a contamination control strategy, provide optimal support in minimizing contamination risks.

Benefits of Dycem in the Pharmaceutical & Biotechnology Industry

SUPERIOR PARTICLE COLLECTION & RETENTION

Dycem mats capture both visible and invisible particulates from shoes and wheels, reducing contamination in cleanrooms and controlled areas by up to 99.9%.

REDUCE MICROBIAL CONTAMINATION CONCERNS

Dycem mats, equipped with Polygiene BioMaster, minimize microbial contamination in critical areas for pharmaceutical and biotechnology customers, ensuring peace of mind.

COST-EFFECTIVE, SUSTAINABLE ALTERNATIVE

Dycem mats, with a lifespan of over 3 years, provide a quick ROI for pharmaceutical and biotechnology manufacturers, along with a reduced carbon footprint compared to disposable options.

Where To Use Dycem Mats

  • GMP controlled areas 
  • Entrances to cleanrooms 
  • Gowning & air showers 
  • Pedestrian & material airlocks 
  • Between production lines 
  • Material & product transfer areas 
  • Packaging areas
Go to article: Home | Pharma’s path to Net Zero: Targeting Scope 3 emissionsGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: DycemGo to article: In DepthGo to article: Pharma’s path to Net Zero: Targeting Scope 3 emissions Go to article: Profit vs inquiry: Clash of objectives in academic and commercial trialsGo to article: CTO Europe 2023: A snapshot of challenges and opportunities in oncology Go to article: The future of cell and gene therapy manufacturing Go to article: VPAS is dead, long live VPAGGo to article: Q&A: European Pharmaceutical legislation: hindrance or help?Go to article: NatoliGo to article: NiproGo to article: YearbookGo to article: Yearbook contentsGo to article: UK’s pharma regulatory scene reckons with changes in 2023Go to article: Pharma breakthroughs: 10 novel drug approvals that made headlines in 2023Go to article: Top themes of 2023: AI, precision medicine, virtual care, digital therapeutics Go to article: Humira biosimilars set the stage for long-awaited 2023 US launchesGo to article: Inside the hunt for an Alzheimer’s disease vaccineGo to article: Pathbreakers: The journey of first genericsGo to article: NASH drugs race to cross the finish lineGo to article: Fighting AMR with a value and subscription modelGo to article: Cancer treatment uncertainty: European nations struggle with drug shortages Go to article: Why are haemophilia gene therapies so expensive? Go to article: Top themes for the healthcare sector in 2024 Go to article: ListingsGo to article: EventsGo to article: The top 100 most innovative companies in the US in 2023Go to article: Buyer's GuidesGo to article: Next issue